Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Thyroid Gland01:23

The Thyroid Gland

4.2K
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
4.2K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

5.0K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

644
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
644
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

530
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
530

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Orbital metastasis in advanced gallbladder and biliary tract malignancy.

BMJ case reports·2025
Same author

Tattoo-associated lacrimal gland enlargement and sarcoidosis.

American journal of ophthalmology case reports·2023
Same author

Alemtuzumab-Induced Thyroid Eye Disease: A Comprehensive Case Series and Review of the Literature.

Ophthalmic plastic and reconstructive surgery·2023
Same author

Transcutaneous retrobulbar amphotericin B for rhino-orbital-cerebral mucormycosis: a multi-center retrospective comparative study.

Orbit (Amsterdam, Netherlands)·2023
Same author

A Contemporary Review of the Role of Facial Prostheses in Complex Facial Reconstruction.

Plastic and reconstructive surgery·2023
Same author

Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.

Ophthalmic plastic and reconstructive surgery·2022

Related Experiment Video

Updated: Aug 30, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Teprotumumab (Tepezza) for Thyroid Eye Disease.

Steven M Couch1

  • 1John F. Hardesty MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.

Missouri Medicine
|August 29, 2022
PubMed
Summary
This summary is machine-generated.

Thyroid eye disease (TED), an autoimmune condition, causes inflammation and disfigurement. Teprotumumab offers significant improvements in proptosis, double vision, and quality of life during its 24-week treatment course.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

3.9K

Related Experiment Videos

Last Updated: Aug 30, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

3.9K

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Immunology

Background:

  • Thyroid eye disease (TED) involves immune-mediated inflammation of orbital tissues, leading to disfigurement.
  • TED presents in active inflammatory and quiescent phases, managed by therapies and surgery.
  • Current treatments aim to control inflammation and improve clinical outcomes.

Purpose of the Study:

  • To evaluate the efficacy of teprotumumab in treating thyroid eye disease.
  • To assess the impact of teprotumumab on key clinical aspects of TED.

Main Methods:

  • A 24-week course of teprotumumab therapy was administered.
  • Clinical outcomes including proptosis, diplopia, and quality of life were assessed.

Main Results:

  • Teprotumumab demonstrated significant improvements in proptosis (eye protrusion).
  • Patients experienced notable reductions in diplopia (double vision).
  • Quality of life scores significantly improved following treatment.

Conclusions:

  • Teprotumumab is an effective therapy for thyroid eye disease.
  • The drug addresses key symptoms like proptosis and diplopia.
  • Teprotumumab enhances the quality of life for TED patients.